Neutralizing prolactin receptor antibodies and their therapeutic use

US9241989B2 · kind B2 · utility

Assignee

• Bayer Intellectual Property GmbH · DE

Inventors

• Christiane Otto · Berlin, DE
• Siegmund Wolf · Bad Klosterlausnitz, DE
• Christoph Freiberg · Wuppertal, DE
• Axel Harrenga · Wuppertal, DE
• Simone Greven · Dormagen, DE
• Mark Trautwein · Whippany, US
• Sandra Bruder · Leverkusen, DE
• Andrea Eicker · Rheydt, DE
• Andreas Wilmen · Neunburg vorm Wald, DE

Key dates

• Filing date: Nov 18, 2010
• Grant date: Jan 26, 2016
• Expiry date: Nov 21, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07K2317/76
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to the neutralizing prolactin receptor antibody 005-C04, as well as maturated forms thereof, and antigen binding fragments, pharmaceutical compositions containing them and their use in the treatment or prevention of benign disorders and indications mediated by the prolactin receptor such as endometriosis, adenomyosis, non-hormonal female contraception, benign breast disease and mastalgia, lactation inhibition, benign prostate hyperplasia, fibroids, hyper- and normoprolactinemic hair loss, and cotreatment in combined hormone therapy to inhibit mammary epithelial cell proliferation. The antibodies of the invention block prolactin receptor-mediated signaling.